Ginsenoside Rg2

Ginsenoside Rg2 suppresses the hepatic glucose production via AMPK-induced phosphorylation of GSK3β and induction of SHP gene expression, suggests that it has therapeutic potential for type 2 diabetic patients.^[1]

Ginsenoside Rg2 inhibits nicotinic acetylcholine receptor-mediated Na+ influx and channel activity; it also inhibits the 5-HT-induced inward peak current (I5-HT) in dose dependent and reversible manner, the half-inhibitory concentrations (IC50) of ginsenoside Rg2 is 22.3 +/- 4.6 microM, suggests that it might regulate the 5-HT3A receptors that are expressed in Xenopus oocytes.^[2]

Ginsenoside Rg2 can reduce LPS-mediated THP-1 monocyte adhesion to HUVEC, in a concentration-dependent manne, it may provide direct vascular benefits with inhibition of leukocyte adhesion into vascular wall thereby providing protection against vascular inflammatory disease.^[3]

Ginsenoside Rg2 protects cells against UVB-induced genotoxicity by increasing DNA repair, in possible association with modulation of protein levels involved in p53 signaling pathway.^[4]

Ginsenoside Rg2 improves learning and memory through mechanisms related to anti-apoptosis in MID rats, indicates that it may represent a potential neurorestorative treatment strategy for vascular dementia or other ischemic insults.^[5]

Ginsenoside Rg2 has protective effects against H2O2-induced injury and apoptosis in H9c2 cells.^[6]

[1] Yuan H D, Kim D Y, Quan H Y, et al. Chem-Bioll Interact, 2012, 195(1):35-42.

[2] Choi S, Lee J H, Oh S, et al. Mol Cells, 2003, 15(1):108-13.

[3] Cho Y S, Chan H K, Ha T S, et al. Korean J Physiol Pham 2013, 17(2):133-7.

[4] Ha S E, Shin D H, Kim H D, et al. N-S Arch Pharmacol, 2010, 382(1):89-101.

[5] Gong Z H, Liu M X, Gong L L, et al. Prog in Modern Biomed, 2010,10(06):1069-75.

[6] Fu W, Sui D, Yu X, et al. Int J Clin Exp Med, 2015, 8(11):19938-47.

[7] Yu M, Mi H, Jiao L. China Pharmacist, 2005, 8(12):1017-9.